Anticancer activity of HS-527, a novel inhibitor targeting PI3-kinase in human pancreatic cancer cells

Cancer Letters

Volumn 353, Issue 1, 2014, Pages 68-77

  Ryu, Ye Lim ^a   Jung, Kyung Hee ^a   Son, Mi Kwon ^a   Yan, Hong Hua ^a   Kim, Soo Jung ^a   Shin, Sanghye ^b   Hong, Sungwoo ^b   Hong, Soon Sun ^a  

^a Inha University School of Medicine   (South Korea)

^b Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

Author keywords

Angiogenesis; Apoptosis; HS 527; Pancreatic cancer; PI3K

Indexed keywords

2 AMINO N,N DIMETHYL 5 [3 (2 METHYLPYRIDIN 4 YL) 1H PYRROLO[2,3 B]PYRIDIN 5 YL]PYRIDINE 3 SULFONAMIDE; ANTINEOPLASTIC AGENT; CASPASE 3; GEMCITABINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN KINASE B; S6 KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN; 2-AMINO-N,N-DIMETHYL-5-(3-(2-METHYLPYRIDIN-4-YL)-1H-PYRROLO(2,3-B)PYRIDIN-5-YL)PYRIDINE-3-SULFONAMIDE); 2 AMINO N,N DIMETHYL 5 (3 (2 METHYLPYRIDIN 4 YL) 1H PYRROLO(2,3 B)PYRIDIN 5 YL)PYRIDINE 3 SULFONAMIDE); AMINOPYRIDINE DERIVATIVE; ANGIOGENESIS INHIBITOR; APOPTOSIS REGULATORY PROTEIN; HIF1A PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; SULFONAMIDE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; BINDING SITE; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING; DRUG SPECIFICITY; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; HUMAN CELL; MITOSIS INHIBITION; MOUSE; NONHUMAN; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANGIOGENESIS; ANIMAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; HS-527; METABOLISM; MOLECULARLY TARGETED THERAPY; PANCREAS CANCER; PANCREAS TUMOR; PATHOLOGY; PI3K; TIME; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULARIZATION;

ANGIOGENESIS; APOPTOSIS; HS-527; PANCREATIC CANCER; PI3K;

AMINOPYRIDINES; ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PHYSIOLOGIC; PANCREATIC NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SULFONAMIDES; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84908373267     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.07.001     Document Type: Article

References (36)

1. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., Feuer E.J., Thun M.J. Cancer statistics. CA Cancer J. Clin. 2005, 55:10-30.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA Cancer J. Clin. 2013, 63:11-30.
3. Zhong H., Sanchez C., Spitrzer D., Plambeck-Suess S., Gibbs J., Hawkins W.G., Denardo D., Gao F., Pufahl R.A., Lockhart A.C., et al. Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models. PLoS ONE 2013, 8:e77243.
4. Wang Z., Li Y., Ahmad A., Banerjee S., Azmi A.S., Kong D., Sarkar F.H. Pancreatic cancer: understanding and overcoming chemoresistance. Nat. Rev. Gastroen. Hepatol. 2011, 8:27-33.
5. Burris H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., Cripps M.C., Portenoy R.K., Storniolo A.M., Tarassoff P., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997, 15:2403-2413.
6. Akinleye A., Avvaru P., Furqan M., Song Y., Liu D. Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J. Hematol. Oncol. 2013, 6:88.
7. Yuan T.L., Cantley L.C. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008, 27:5497-5510.
8. Geering B., Cutillas P.R., Vanhaesebroeck B. Regulation of class IA PI3Ks: is there a role for monomeric PI3K subunits?. Biochem. Soc. Trans. 2007, 35:199-203.
9. Wallin J.J., Edgar K.A., Guan J., Berry M., Prior W.W., Lee L., Lesnick J.D., Lewis C., Nonomiya J., Pang J., et al. GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Mol. Cancer Ther. 2011, 10:2426-2436.
10. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2002, 2:489-501.
11. Matthaios D., Zarogoulidis P., Balgouranidou I., Chatzaki E., Kakolyris S. Molecular pathogenesis of pancreatic cancer and clinical perspectives. Oncology 2011, 81:259-272.
12. Maitra A., Hruban R.H. Pancreatic cancer. Annu. Rev. Pathol. 2008, 3:157-188.
13. Zachary I. VEGF signalling: integration and multi-tasking in endothelial cell biology. Biochem. Soc. Trans. 2003, 31:1171-1177.
14. Bondar V.M., Sweeney-Gotsch B., Andreeff M., Mills G.B., McConkey D.J. Inhibition of the phosphatidylinositol 3'-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol. Cancer Ther. 2002, 1:989-997.
15. Hollestelle A., Elstrodt F., Nagel J.H., Kallemeijn W.W., Schutte M. Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines. Mol. Cancer Res. 2007, 5:195-201.
16. Lee H., Kim S.J., Jung K.H., Son M.K., Yan H.H., Hong S., Hong S.S. A novel imidazopyridine PI3K inhibitor with anticancer activity in non-small cell lung cancer cells. Oncol. Rep. 2013, 30:863-869.
17. Edling C.E., Selvaggi F., Buus R., Maffucci T., Di Sebastiano P., Friess H., Innocenti P., Kocher H.M., Falasca M. Key role of phosphoinositide 3-kinase class IB in pancreatic cancer. Clin. Cancer Res. 2010, 16:4928-4937.
18. Li J., Liang X., Yang X. Ursolic acid inhibits growth and induces apoptosis in gemcitabine-resistant human pancreatic cancer via the JNK and PI3K/Akt/NF-kappaB pathways. Oncol. Rep. 2012, 28:501-510.
19. Perugini R.A., McDade T.P., Vittimberga F.J., Callery M.P. Pancreatic cancer cell proliferation is phosphatidylinositol 3-kinase dependent. J. Surg. Res. 2000, 90:39-44.
20. Fahy B.N., Schlieman M., Virudachalam S., Bold R.J. AKT inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2. Br. J. Cancer 2003, 89:391-397.
21. Schlieman M.G., Fahy B.N., Ramsamooj R., Beckett L., Bold R.J. Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br. J. Cancer 2003, 89:2110-2115.
22. Wendel H.G., De Stanchina E., Fridman J.S., Malina A., Ray S., Kogan S., Cordon-Cardo C., Pelletier J., Lowe S.W. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004, 428:332-337.
23. Gehrmann M., Schmidt M., Brase J.C., Roos P., Hengstler J.G. Prediction of paclitaxel resistance in breast cancer: is CYP1B1*3 a new factor of influence?. Pharmacogenomics 2008, 9:969-974.
24. Smith L., Watson M.B., O'Kane S.L., Drew P.J., Lind M.J., Cawkwell L. The analysis of doxorubicin resistance in human breast cancer cells using antibody microarrays. Mol. Cancer Ther. 2006, 5:2115-2120.
25. Mori-Iwamoto S., Kuramitsu Y., Ryozawa S., Taba K., Fujimoto M., Okita K., Nakamura K., Sakaida I. A proteomic profiling of gemcitabine resistance in pancreatic cancer cell lines. Mol. Med. Rep. 2008, 1:429-434.
26. Ghobrial I.M., Witzig T.E., Adjei A.A. Targeting apoptosis pathways in cancer therapy. CA Cancer J. Clin. 2005, 55:178-194.
27. Horikawa K., Nakakuma H., Kawaguchi T., Iwamoto N., Nagakura S., Kagimoto T., Takatsuki K. Apoptosis resistance of blood cells from patients with paroxysmal nocturnal hemoglobinuria, aplastic anemia, and myelodysplastic syndrome. Blood 1997, 90:2716-2722.
28. Petronilli V., Penzo D., Scorrano L., Bernardi P., Di Lisa F. The mitochondrial permeability transition, release of cytochrome c and cell death. Correlation with the duration of pore openings in situ. J. Biol. Chem. 2001, 276:12030-12034.
29. Kaufmann S.H., Hengartner M.O. Programmed cell death: alive and well in the new millennium. Trends Cell Biol. 2001, 11:526-534.
30. Altieri D.C. Survivin and IAP proteins in cell-death mechanisms. Biochem. J. 2010, 430:199-205.
31. Tsuruta F., Masuyama N., Gotoh Y. The phosphatidylinositol 3-kinase (PI3K)-Akt pathway suppresses Bax translocation to mitochondria. J. Biol. Chem. 2002, 277:14040-14047.
32. Folkman J. Angiogenesis. Annu. Rev. Med. 2006, 57:1-18.
33. Weis S.M., Cheresh D.A. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat. Med. 2011, 17:1359-1370.
34. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 2003, 3:721-732.
35. Arsham A.M., Plas D.R., Thompson C.B., Simon M.C. Akt and hypoxia-inducible factor-1 independently enhance tumor growth and angiogenesis. Cancer Res. 2004, 64:3500-3507.
36. Jiang B.H., Liu L.Z. PI3K/PTEN signaling in tumorigenesis and angiogenesis. Biochim. Biophys. Acta 2008, 1784:150-158.